Research graph
References from Investigating how HIV-1 antiretrovirals differentially behave as substrates and inhibitors of P-glycoprotein via molecular dynamics simulations. Local targets link to admitted publications; unresolved targets remain external evidence.
HIV DNA set point is rapidly established in acute hiv infection and dramatically reduced by early ART
10.1016/j.ebiom.2016.07.024 · 2016 · External reference
How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs?
10.1097/coh.0000000000000122 · 2015 · External reference
10.1128/jvi.01046-14
10.1128/jvi.01046-14 · External reference
Impact of the timing of initiation of antiretroviral therapy during primary HIV-1 INfection on the Decay of Cell-associated HIV-DNA
10.1093/cid/civ171 · 2015 · External reference
10.3390/vaccines9080867
10.3390/vaccines9080867 · External reference
HIV in the brain: identifying viral reservoirs and addressing the challenges of an HIV cure
10.3390/vaccines9080867 · 2021 · External reference
Microglial Cells: the main HIV-1 reservoir in the brain
10.3389/fcimb.2019.00362 · 2019 · External reference
Molecular and cellular mechanisms of neuronal cell death in HIV dementia
2005 · External reference
10.1097/qco.0000000000000328
10.1097/qco.0000000000000328 · External reference
The paradox of HIV blood–brain barrier penetrance and antiretroviral drug delivery deficiencies
10.1016/j.tins.2020.06.007 · 2020 · External reference
P-glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of saquinavir in mice
10.1124/jpet.104.076216 · 2005 · External reference
Evolving new-age strategies to transport therapeutics across the blood-brain-barrier
10.1016/j.ijpharm.2021.120351 · 2021 · External reference
Clinical perspective of FDA approved drugs with P-glycoprotein inhibition activities for potential cancer therapeutics
2020 · External reference
P-glycoprotein: new insights into structure, physiological function, regulation and alterations in disease
10.1016/j.heliyon.2022.e09777 · 2022 · External reference
10.3390/molecules25246006
10.3390/molecules25246006 · External reference
10.1021/ct300083m
10.1021/ct300083m · External reference
10.1111/j.1432-1033.1997.00130.x
10.1111/j.1432-1033.1997.00130.x · External reference
Molecular docking characterizes substrate-binding sites and efflux modulation mechanisms within P-Glycoprotein
10.1021/ci400195v · 2013 · External reference
10.1016/j.tips.2004.06.002
10.1016/j.tips.2004.06.002 · External reference
Anti-HIV and anti-hepatitis C virus drugs inhibit P-glycoprotein efflux activity in Caco-2 cells and precision-cut rat and human intestinal slices
10.1128/aac.00910-19 · 2019 · External reference
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance
10.1016/j.clpt.2003.09.012 · 2004 · External reference
10.1016/j.ejps.2013.04.032
10.1016/j.ejps.2013.04.032 · External reference
HIV protease inhibitors: a review of molecular selectivity and toxicity
2015 · External reference
ürgen et al. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833
10.1016/s0006-2952(99)00026-x · 1999 · External reference
Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein
10.1016/j.bcp.2007.01.027 · 2007 · External reference
P-Glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines HHS public access
10.1248/bpb.32.1588 · 2009 · External reference
10.1080/07391102.2020.1821780
10.1080/07391102.2020.1821780 · External reference
10.1021/acs.molpharmaceut.7b00133
10.1021/acs.molpharmaceut.7b00133 · External reference
10.1016/j.ejps.2012.10.002
10.1016/j.ejps.2012.10.002 · External reference
10.1016/j.ejps.2011.04.007
10.1016/j.ejps.2011.04.007 · External reference
10.1126/science.aar7389
10.1126/science.aar7389 · External reference
10.1155/2017/8274927
10.1155/2017/8274927 · External reference
Co-treatment With HIV protease inhibitor nelfinavir greatly increases late-phase apoptosis of drug-resistant KBV20C cancer cells independently of P-glycoprotein inhibition
10.21873/anticanres.13524 · 2019 · External reference
10.1021/acs.molpharmaceut.7b00133
10.1021/acs.molpharmaceut.7b00133 · External reference
Blood–brain and retinal barriers show dissimilar ABC transporter impacts and concealed effect of P‐glycoprotein on a novel verapamil influx carrier
10.1111/bph.13376 · 2016 · External reference
Acute liver failure enhances oral plasma exposure of zidovudine in rats by downregulation of hepatic UGT2B7 and intestinal P-gp
10.1038/aps.2017.54 · 2017 · External reference
10.1016/j.ejps.2011.04.007
10.1016/j.ejps.2011.04.007 · External reference
Insights into the mechanism of drug resistance: X-ray structure analysis of multi-drug resistant HIV-1 protease ritonavir complex
10.1016/j.bbrc.2012.12.127 · 2013 · External reference
Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir
10.1002/prot.21304 · 2007 · External reference
Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants
10.1016/j.jmb.2007.09.083 · 2007 · External reference
The higher barrier of darunavir and tipranavir resistance for HIV-1 protease
10.1016/j.bbrc.2011.08.045 · 2011 · External reference
A new drug binding subsite on human serum albumin and drug–drug interaction studied by X-ray crystallography.
10.1016/j.jsb.2007.12.004 · 2008 · External reference
Unresolved reference
2009 · External reference
Automatic atom type and bond type perception in molecular mechanical calculations
10.1016/j.jmgm.2005.12.005 · 2006 · External reference
10.1021/ja00074a030
10.1021/ja00074a030 · External reference
10.1002/jcc.20290
10.1002/jcc.20290 · External reference
ACPYPE - AnteChamber PYthon Parser interfacE
10.1186/1756-0500-5-367 · 2012 · External reference
Improved side-chain torsion potentials for the Amber ff99SB protein force field
10.1002/prot.22711 · 2010 · External reference
ATP-Magnesium coordination: protein structure-based force field evaluation and corrections
10.1021/acs.jctc.0c01205 · 2021 · External reference
Development of polyphosphate parameters for use with the AMBER force field
10.1002/jcc.10262 · 2003 · External reference
10.1080/07391102.2020.1821780
10.1080/07391102.2020.1821780 · External reference
10.1038/s41586-021-03819-2
10.1038/s41586-021-03819-2 · External reference
10.1093/nar/gkab1061
10.1093/nar/gkab1061 · External reference
10.1126/science.aav7102
10.1126/science.aav7102 · External reference
10.1021/acs.jmedchem.1c01272
10.1021/acs.jmedchem.1c01272 · External reference
10.1038/nprot.2016.051
10.1038/nprot.2016.051 · External reference
10.1002/jcc.21334
10.1002/jcc.21334 · External reference
AutoDock vina 1.2.0: new docking methods, expanded force field, and python bindings
10.1021/acs.jcim.1c00203 · 2021 · External reference
Unresolved reference
External reference
Simulation of activation free energies in molecular systems
10.1063/1.472061 · 1996 · External reference
10.1063/1.2408420
10.1063/1.2408420 · External reference
10.1063/1.448118
10.1063/1.448118 · External reference
10.1063/1.328693
10.1063/1.328693 · External reference
LINCS: a linear constraint solver for molecular simulations
10.1002/(sici)1096-987x(199709)18:12<1463::aid-jcc4>3.0.co;2-h · 1997 · External reference
10.1063/1.464397
10.1063/1.464397 · External reference
Best practices for quantification of uncertainty and sampling quality in molecular simulations [Article v1.0
2018 · External reference
10.1021/ci500020m
10.1021/ci500020m · External reference
10.3389/fmolb.2017.00087
10.3389/fmolb.2017.00087 · External reference
Visual molecular dynamics
10.1016/0263-7855(96)00018-5 · 1996 · External reference
10.1002/1873-3468.13992
10.1002/1873-3468.13992 · External reference
PubChem 2023 update
2022 · External reference
